Table 3 Molecular analysis of crawling-type adenocarcinomas (CRAs) and conventional differentiated adenocarcinomas (CDAs)
From: Analysis of clinicopathological and molecular features of crawling-type gastric adenocarcinoma
CRA (%) | CDA (%) | P-value | |
|---|---|---|---|
Total (lesions) | 51 (100.0) | 126 (100.0) | |
TP53 gene mutation | < 0.01 | ||
Positive | 19 (37.3) | 10 (7.9) | |
Negative | 32 (62.7) | 116 (92.1) | |
KRAS gene mutation | 0.09 | ||
Positive | 0 (0.0) | 7 (5.6) | |
Negative | 51 (100.0) | 119 (94.4) | |
BRAF gene mutation | 0.64 | ||
Positive | 1 (2.0) | 0 (0.0) | |
Negative | 50 (98.0) | 126 (100.0) | |
Microsatellite stability status | 0.59 | ||
Microsatellite instability (MSI) | 5 (9.8) | 16 (12.7) | |
Microsatellite stable (MSS) | 46 (90.2) | 110 (87.3) | |
DNA methylation statusa | < 0.01 | ||
High methylated epigenotype | 6/45 (13.3) | 32 (25.4) | |
Intermediate methylated epigenotype | 12/45 (26.7)* | 64 (50.8)* | |
Low methylated epigenotype | 27/45 (60.0)** | 30 (23.8)** | |
MLH-1 methylation status | 0.03 | ||
Hypermethylated | 1 (2.0) | 16 (12.7) | |
No hypermethylation | 50 (98.0) | 110 (87.3) | |
Allelic imbalancesa | |||
1p | 17/43 (39.5) | 10/93 (10.8) | < 0.01 |
3p | 9/37 (24.3) | 17/104 (16.3) | 0.28 |
4p | 17/36 (47.2) | 15/111 (13.5) | < 0.01 |
5q | 17/44 (38.6) | 31/110 (28.2) | 0.21 |
8p | 16/25 (64.0) | 20/105 (19.0) | < 0.01 |
9p | 10/23 (43.5) | 18/103 (17.5) | < 0.01 |
13q | 4/12 (33.3) | 13/75 (17.3) | 0.19 |
17p (TP53) | 10/34 (29.4) | 29/94 (30.9) | 0.95 |
18q | 21/48 (43.8) | 18/112 (16.1) | < 0.01 |
22q | 12/23 (52.2) | 20/110 (18.2) | < 0.01 |